Introduction
Melanoma can occur anywhere melanin-producing cells exist, and thus it is often found on the mucosal surface of the vulva, on the anorectal mucosa, in the nasal cavity, or in the oral cavity. The incidence of melanoma has increased over the last four decades, and in the case of metastatic melanoma, patients have a very poor prognosis with a low five-year survival rate [1] [2] [3] [4] .
Several techniques have been established for cancer treatment, including chemotherapies, radiotherapies, and immunotherapies. Recently, targeted immunotherapies using antibodies have been the subject of investigation, and these are referred to as next generation therapies [5] . When combined with a radioisotope or other toxin, antibodies against antigens enriched on cancer cells can selectively kill those cells and effectively treat the cancer [6, 7] . However, non-specific reactivity to normal cells can create unwanted toxicity, and the immunotoxins can cause secondary antibody-antigen interactions with existing antibodies, thus limiting their effectiveness against cancer cells. Recently, nanoparticles have been applied in cancer treatment to avoid the problems plaguing chemical anticancer
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International Publisher drugs. Advances in nano-technology have resulted in the use of gold nanoparticles (GNP) as diagnostic and drug delivery tools [8, 9] . The GNP is suitable for use as a marker of tumor cells, and if antigen-specific ligands or antibodies are bound to nanoparticles, the effect can be maximized while avoiding the pharmacological side-effects.
Plasma is a highly reactive gas with potential biomedical applications. A number of previous reports have shown plasma to be effective for killing cancer cells, sterilizing instruments, causing coagulation, facilitating wound healing, and rejuvenating skin [10] [11] [12] . However, plasma alone is unable to kill cancer cells selectively, since there is no way for it to target cancer cells over normal cells. Plasma consists of electrons and radical ions in an electric field, and because of this it can react with and activate GNP [13, 14] . In this study, plasma was used along with GNP conjugated to antibodies targeting cancer-cell specific proteins to kill cancer cells selectively [15] . Cancer specific antibody-conjugated GNP preferentially bind to cancer cells that express the target antigen at high levels. The stimulation of the GNP by plasma results in severe stress to the cancer cells, leading to cell death. Therefore, we manufactured a GNP-antibody conjugate using a tumor specific antibody known to be both safe and able to enter cells.
We chose to use an antibody targeting focal adhesion kinase (FAK), a protein that is over-expressed in melanoma cells [16] . FAK is a tyrosine kinase that is involved in early integrin/extracellular matrix (ECM) signaling that has been shown to modulate cancer cell migration, invasion, and survival [17] [18] [19] . Increased expression of FAK is crucial for the survival, growth, and metastasis of melanoma cells [20] . We expected that conjugation of an antibody against phosphorylated-FAK (p-FAK) to GNP (p-FAK-GNP) would result in a conjugate with high selectivity for melanoma cells. The plasma-stimulated p-FAK-GNP should inhibit the activity of FAK and thereby inhibit cellular functions within melanoma cells specifically, leading to their death. Therefore, this study was performed to investigate the possibility of selectively killing G361 human skin malignant melanoma cells with p-FAK-GNP and plasma, and to understand the molecular pathways involved.
Materials and Methods

Materials
The following chemicals and reagents were obtained from the indicated companies: The RNase A, proteinase K, leupeptin, aprotinin, PI, phenylmethylsulfonyl fluoride (PMSF), and Ponceau S were purchased from Sigma (St Louis, MO, USA). SuperSignal West Femto enhanced chemiluminescence western blotting detection reagent was from Pierce (Rockford, IL, USA).
Antibodies
The monoclonal mouse anti-human p-FAK antibody was obtained from Millipore (CA, USA). The rabbit polyclonal anti-human p-paxillin antibody was purchased from Cell Signaling Technology, Inc. (Boston, MA). The rabbit polyclonal anti-human NEU and DFF 45 antibodies were purchased from Santa Cruz Biotechnology (CA, USA). Monoclonal mouse anti-human NEU, FAK, BAX, Bcl-2, GAPDH, Caspase 9, and Caspase 3 antibodies were purchased from Santa Cruz Biotechnology (CA, USA). The horseradish peroxidase conjugated goat anti-mouse and anti-Rabbit IgG were purchased from Santa Cruz Biotechnology (CA, USA).
Cell culture
The G361 and HaCaT cells were cultured in Roswell Park Memorial Institute 1640 media and Dulbecco's modified Eagle medium supplemented with 25 mM Hepes, 100 μg/mL penicillin/streptomycin, 4 mM L-glutamine, and 10 % fetal bovine serum. Cultures were maintained at 37 °C in a 5 % CO2 atmosphere in a humidified incubator.
GNP conjugated with antibodies
To make GNP-antibody conjugates, an aqueous solution of 11-mercaptoundecanoic acid (MUA) (0.1 mg/mL) is added to a colloidal gold suspension and incubated overnight. MUA-modified GNP is then treated with a mixture of 1 mM N-hydroxysuccinimide (NHS) and 1 mM N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide for 20 min. GNP with exposed surface NHS-termini are then incubated with p-FAK antibodies in phosphate buffered saline (PBS) (1 mM, pH 7.0) for at least 8 h.
G361 and HaCaT cells were treated with p-FAK-GNP for 20min and then fixed in 4% paraformaldehyde. Cells were incubated with goat Alexa 488 anti-mouse secondary antibody for 30 min. Fluorescent images were observed under a Zeiss LSM 700 laser-scanning confocal microscope (Göettingen, Germany).
WST assay
The viability of cells was evaluated in vitro using a WST-1 assay. Cells were seeded at a density of 1 × 10 4 cells per well in a 96-well plate. Cells were then treated with the p-FAK-GNP conjugates. After a 24, 48, or 72 h incubation, 10 µL WST-1 reagent was added to each well, and the absorbance at 450 nm was measured 2 h later using a microplate reader (Quant, Bio-Tek, Highland Park, USA).
Flow cytometry analysis
The G361 cells, including the p-FAK-GNP-treated cells, were seeded into 35 mm diameter dishes at densities of 1 × 10 4 cells/well and incubated for 24 h. Cells were harvested and washed with cold PBS. The cells were then centrifuged at 1500 RPM for 5 min. The cells were then fixed in cold 70 % ethanol for 24 h. The fixed cells were washed with PBS and centrifuged again at 1500 RPM for 5 min. RNase A was added to a concentration of 100 µg/mL to the cells, which were incubated at 37 °C for 30 min and resuspended in PI solution (10 µg/mL). Cells were incubated at 4 °C for 10 min and analyzed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA).
Immunofluorescent staining
Cells were cyto-centrifuged and fixed for 10 min in 4% paraformaldehyde, incubated with AIF, cytochrome c antibody for 1 h at 37℃, washed 3 each for 5 min, and then incubated with goat Alexa 488 and 594 conjugated secondary antibody for 1 h at 37℃.
Cells were mounted with mounting solution. Fluorescent images were observed and analyzed under Zeiss LSM 700 laser-scanning confocal microscope (Göettingen, Germany).
Western blot analysis
For protein analysis, the cells were lysed with a lysis buffer (10 mM Tris/HCl, pH 7.2, 1 % Triton X-100, 150 mM NaCl, 5 mM EDTA, 2 mM PMSF, 2 μg/mL aprotinin, and 2 μg/mL leupeptin) on ice for 1 h. The lysate was clarified by centrifugation at 14000 RPM for 20 min at 4 °C, and the supernatant was obtained. The protein content of the lysate was determined using a Bio-Rad Protein Assay (Bio-Rad laboratories Hercules, CA). The samples (25 μg of lysate) were then boiled for 95 °C for 5 min, the protein was resolved using polyacrylamide SDS gels and transferred to a PVDF membrane. After transfer, the membranes were blocked with a blocking reagent (5 % non-fat milk in TBS-T (20 mM Tris, 150 mM NaCl, 0.1 % Tween 20)) for 1 h. The membranes were incubated for 2 h with the appropriate antibody. The membranes were treated with ECL western blotting reagents for protein detection.
Non-thermal atmospheric pressure plasma source
A schematic diagram of the experimental setup is shown in Fig. 4 . In this case, the size of the device was modified to 10.24 cm 2 to allow a wide treatment area. The other design factors were kept to maintain the plasma characteristics. The mask pattern was etched using a wet etching technique on Cu electrodes, which were surrounding both sides of a polytetrafluoroethylene (PTFE) dielectric surface. The device was connected directly to a high voltage AC power source (15 kV, 22 kHz). The front side of the device was grounded for safety reasons. The plasma operated in ambient air with 500 V (RMS) applied voltage. The applied voltage was controlled and maintained at a specific value to avoid indiscriminate cell death. For the treatment of G361 or HaCaT cells (4 × 10 4 cells) with plasma, the cells were seeded on the glass cover slips (12 mm diameter) as shown in Fig.  4A . Just before plasma treatment, the cover glasses containing the cells were placed under a thin, tetragonal plasma generator (Fig. 4b) . The distance between cells and the device was kept at 2 mm during the 30 s treatment. For the 24 h before the treatment, cells were incubated in growth media with or without p-FAK-GNPs. Just before the treatment, the cover glasses were washed with PBS to remove non-selectively bound and unbound p-FAK-GNP conjugates.
Transmission electron microscopy of cell morphology
G361 cells were grown on Aclar film coated with collagen. After treatments as indicated, the G361 cells were fixed at 4 °C for 1.5 h with a fixative of 4 % PFA and 2.5 % glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Cells were then rinsed with phosphate buffer and after fixation in 1 % osmium tetroxide, the cells were put through a graded ethanol series. Cells were removed from the Aclar film and placed in a glass scintillation vial containing propylene oxide (PO). Dehydration was performed with three sequential incubations, each for 5 min in fresh PO, and one final incubation in fresh PO for 10 min. Cells were infiltrated with a mixture of 1:1 Epon:PO for 1 h, then with a 2:1 mixture for 2 h, then with pure Epon for 2 h, and finally with Epon and an added accelerator for 42-48 h. Cells were embedded in Epon, and ultrathin sections were examined using a JEM 1200EX-II transmission electron microscope (Jeol; Tokyo, Japan).
Statistical Analysis
Three independent experimental replicates were performed for each experiment, and the standard deviation is indicated with error-bars in the Figures. The treated, co-treated, and control group results were compared for statistically significant differences (p < 0.001, 0.01, and 0.05) using paired T-tests that were performed with the PASW Statistics 18 (formerly SPSS) software.
Results
The levels of phosphorylated FAK in G361 melanoma cells
The levels of p-FAK in G361 human melanoma cells were compared with those in HaCaT normal human keratinocytes by western blot analysis. G361 cells had large amounts of p-FAK protein, whereas p-FAK was barely detectable in normal HaCaT cells (Fig. 1A ).
An immunofluorescence assay was used to elucidate whether GNP conjugated with Alexa Fluor 488 antibodies could flow into cells. As shown in Fig.  1B , GNP were observed in the cytosol of both G361 and HaCaT cells after four hours of incubation. When cells were treated with p-FAK-GNP that were similarly fluorescently labeled, the p-FAK-GNP were mainly localized at cell membranes of G361 cells, where the p-FAK likely localized (Fig. 1C) . In the case of HaCaT, the localization pattern of the p-FAK-GNP was very similar to that of GNP themselves, consistent with the observed lack of FAK expression.
Preferential inhibition of melanoma cells by p-FAK-GNP
As shown in Fig 2A, treatment with p-FAK antibodies inhibited the viability of G361 cells in a time-dependent manner (24 h, 94 % viability; 48 h, 57 % viability; and 72 h, 11 % viability). Interestingly, treatment of G361 cells with an equal concentration of p-FAK-GNP led to more rapid growth inhibition (24 h, 72 % viability; 48 h, 14 % viability; and 72 h, 2 % viability; Fig. 2B ). In contrast, the viability of HaCaT cells was barely affected by p-FAK-GNP (Fig. 2C) . Therefore, the p-FAK-GNP showed anti-proliferative effects against G361 cells specifically.
The changes in cellular signaling proteins known to be activated by FAK were examined in G361 cells treated with p-FAK-GNP by western blot analysis. The level of activated paxillin, the main target protein of FAK, was significantly decreased following treatment with p-FAK-GNP, although the levels of FAK and p-FAK were also slightly decreased. Furthermore, levels of NEU, a protein upstream of FAK, and phosphorylated-NEU (p-NEU) were significantly decreased at 24 h, and then undetectable at 48 h in G361 cells treated with p-FAK-GNP. This result suggests that the p-FAK-GNP can block other signaling pathways (Fig. 2D) 
Induction of apoptosis in G361 cells by p-FAK-GNP
G361 cells were treated with p-FAK-GNPs for 0 to 48 h and their cell cycle progress was monitored using flow cytometry with propidium iodide (PI) staining (Fig. 3A ). There were no significant changes in the cell cycle until apoptosis began to increase. A significant increase was detected in the sub-G1 population of cells exposed to p-FAK-GNP for more than 24 h. Interestingly, the number of cells in all cell cycle phases (G1, S, and G2/M) gradually decreased as the number of apoptotic cells increased.
After p-FAK-GNP treatment, the subcellular localizations of mitochondrial apoptosis-related factors were examined to confirm apoptosis at the molecular level. Immunofluorescence microscopy showed that cytochrome c (Fig. 3B) and AIF (Fig. 3C) in the control cells were localized in punctuate patterns, whereas those proteins were diffusely distributed in p-FAK-GNP-treated cells indicating their release from the mitochondria into the cytosol. In particular, the distribution of AIF was primarily cytoplasmic in the control cells, but AIF was observed in the nuclei of cells treated with p-FAK-GNP.
The changes of the expression of proteins related with apoptosis, such as a BAX, Bcl-2, caspase-3, caspase-9, PARP-1 and DFF 45 (also known as ICAD) were examined by western blot assay. As shown in Fig. 3D , sequential activation of apoptotic proteins (caspase-9, caspase-3, PARP-1, and DFF 45) was observed after p-FAK-GNP treatment in G361 cells. A significant decrease in the level of the anti-apoptotic protein Bcl-2, coupled with an increase in the apoptosis-promoting BAX, was detected in cells treated with p-FAK-GNP for 48 h.
The selective killing effect of plasma and p-FAK-GNP on G361 cells
Next, we examined the effect of plasma on p-FAK-GNP-mediated cell death. As shown in Fig.  5A , the cells exposed to plasma showed mild induction of apoptosis (about 19.5 % of G361 cells, and 14 % of HaCaT cells). When G361 cells treated with p-FAK-GNP were exposed to the plasma, the death rate was significantly increased to 72.6 %. In contrast, in the case of HaCaT cells, the combined treatment of p-FAK-GNP and plasma resulted in only a moderate increase in death rate (23.8 %).
Transmission electron microscopy was performed in order to explore the effect of plasma with or without p-FAK-GNP on the morphology of G361 cells. As shown in Fig. 5B , no significant morphological changes were detected in the cells treated with plasma alone. However, cells treated with a combination of plasma and p-FAK-GNP formed many vacuoles and had disrupted cellular membranes. As a final step in this study, the levels of FAK and FAK-regulated proteins were monitored to investigate the molecular mechanisms causing death in G361 cells following treatment with p-FAK-GNP and plasma. In G361 cells without p-FAK-GNP, although plasma treatment slightly decreased the levels of FAK, it did not affect the levels of p-FAK, p-paxillin, NEU, or p-NEU. Conversely, in G361 cells pre-treated with p-FAK-GNP, plasma treatment significantly decreased the levels of FAK, p-FAK, p-paxillin, NEU, and p-NEU (Fig. 5C ).
Discussion
In this study, we investigated the mechanism of death in G361 cells treated with p-FAK-GNP, and cells treated with p-FAK-GNP and plasma treatment. We observed elevated levels of p-FAK in G361 cells compared to HaCaT cells, and confirmed that GNP and p-FAK-GNP can enter cells. The viability and proliferation of G361 cells treated with p-FAK-GNP decreased distinctly over time, whereas the viability of HaCaT cells was barely affected. This suggests that p-FAK is important for G361 melanoma cell survival, and the binding of an anti-p-FAK antibody or p-FAK-GNP inhibits its function. When treated with antibodies against p-FAK alone, the viability of G361 cells decreased after 48 hours. However, in the case of treatment with p-FAK-GNP, the viability of the cells was substantially decreased after 24 hours. This suggests that p-FAK-GNP bind to p-FAK proteins specifically, and the GNP and antibody portions of the p-FAK-GNP may both structurally inhibit the activity of p-FAK, thereby acting synergistically to cause death in G361 cells.
In order to investigate the preferential killing of G361 cells by p-FAK-GNP, we monitored changes in the FAK protein. FAK plays an important role in the construction of focal adhesions between integrin proteins and the ECM. Focal adhesions interact with the cytoskeleton, and are accordingly important for cell morphology, migration, adhesion, and spreading [20] . After several tyrosine residues in FAK have been phosphorylated through the activation of integrin, FAK can then phosphorylate paxillin. Furthermore, paxillin expression has been associated with the expression of NEU in breast cancer cells [22] . NEU is expressed in various cancers including melanoma, and thus it is clinically significant for treatment. When NEU binds a ligand, it activates cell signaling through FAK that promotes the proliferation and metastasis of cancer cells [23] . If focal adhesions are destroyed, cells become detached from the ECM and ultimately die. In this study, we observed not only the degradation of FAK and p-FAK, but also the subsequent destruction of p-paxillin, NEU, and p-NEU in G361 cells treated with p-FAK-GNP. These results indicate that targeting FAK with p-FAK-GNPs leads to the degradation of functionally linked proteins.
Analysis of G361 cells treated with p-FAK-GNP using flow cytometry showed that these cells had an increase in the population of sub-G1 hypodiploid cells, indicating that p-FAK-GNP were causing DNA fragmentation. As a result of this, p-FAK-GNP strongly inhibited G361 cell growth by inducing apoptosis. Apoptosis plays an important role in controlling the homeostasis of an organism, and removing cancer cells. Typically, apoptosis involves various molecules such as caspases, death receptors, and Bcl-2 family proteins. It is induced either by death receptors activating the extrinsic pathway, or by mitochondrial damage activating the intrinsic pathway. Bcl-2 family proteins play an important role in controlling the intrinsic pathway, wherein Bcl-2 and Bcl-XL normally suppress apoptosis by inhibiting the release of cytochrome c. Conversely, BAD, BAX, and BAK-1 promote apoptosis by inducing cytochrome c release [24, 25] . These two sets of proteins usually maintain a constant balance within a healthy cell, allowing survival. After treatment with p-FAK-GNP, AIF was released from the mitochondrial membranes into the cytoplasm, and subsequently entered the nuclei of G361 cells. Cytochrome c also moved from the mitochondrial membrane to the cytoplasm following p-FAK-GNP treatment. Bcl-2 levels were reduced, whereas BAX levels were increased in a time dependent manner. Levels of the active form of caspase 3 increased, and its substrate proteins (PARP-1 and DFF 45) were cleaved. Therefore, the apoptosis of G361 cells induced by p-FAK-GNP was likely a result of the destruction of focal adhesion proteins causing mitochondrial damage and subsequent activation of caspase 3.
In this study, we demonstrated that p-FAK-GNP preferentially induced apoptosis in G361 cells without affecting normal cells. Although p-FAK-GNP alone were effective against G361 cells, we used plasma in order to maximize the lethality of p-FAK-GNP. Because plasma can react with GNP, it can stimulate p-FAK-GNP that preferentially bind to p-FAK in G361 cells. Thus, stimulated GNP could inhibit the activities of the FAK protein, and consequently p-FAK-GNP lead to the cell death. We investigated the lethal effect of plasma and p-FAK-GNP on G361 cells compared to HaCaT cells. The death rate in G361 cells treated with p-FAK-GNP and plasma was over three times the death rate of G361 cells treated with only plasma, or HaCaT cells treated with p-FAK-GNP and plasma. Because HaCaT cells express lower levels of FAK protein, they were also affected by p-FAK-GNP and plasma, but much less than the G361 cells. Considering that cell death was induced by 30 seconds of plasma treatment, the cell death induced by p-FAK-GNP and plasma was induced instantly and selectively. Therefore, this rapid cell death might not be due to apoptosis. This phenomenon is different from apoptosis, and further analysis will be needed to understand it.
In this study, a treatment with a combination of p-FAK-GNP and plasma degraded FAK, p-FAK, p-paxillin, p-NEU, and NEU. While the mere treatment of G361 cells with p-FAK-GNP or plasma did not prevent the expression of FAK, the combined treatment lead to a strong decrease in FAK levels. This result is thought to be due to the energy from the plasma being transferred to the GNP, and the stimulated GNP modifying the structure of the p-FAK protein leading to its inactivation. The destruction of p-FAK reduced the levels of other associated signaling molecules. This momentary loss of cell signaling led to the death of the G361 cells.
Conclusions
Overall, after applying p-FAK-GNP to cancer cells and normal cells, our results show that treatment with plasma kills G361 melanoma cells effectively and selectively. In treated G361 cells, cell signaling molecules such as FAK, p-paxillin, and NEU were destroyed along with FAK. Therefore, based on the selective killing of G361 cells using p-FAK-GNP and short periods of plasma treatment, the results of this study suggest that our approach could be very effective for treating melanoma. As the interaction between GNP and plasma is still under investigation, it is difficult to demonstrate the exact mechanisms, for which a further research will be done to confirm. 
